Table 1.
Comparisons of demographic and clinical data between the groups of different HD access related ESBL-Kp bacteremia
| Source of infection | HD catheter | Fistula | Graft | ALL |
|---|---|---|---|---|
|
Case No |
42 |
7 |
8 |
57 |
|
Male (%) |
33 (78.6) |
6 (85.7) |
6 (75) |
45 (78.9) |
|
Age, years |
64.8 ± 10.0 |
61 ± 10.5 |
65.1 ± 7.8 |
64.4 ± 9.5 |
|
Patients aged >65 years (%) |
24 (57.1) |
3 (42.9) |
5 (62.5) |
32 (56.1) |
|
Admission for infectious diseases (%) |
23 (54.8) |
5 (71.4) |
6 (75) |
34 (59.6) |
|
Significant underlying diseases (%) |
|
|
|
|
| Diabetes mellitus |
15 (35.7) |
4 (57.1) |
7 (87.5) |
26 (45.6) |
| Liver cirrhosis |
5 (11.9) |
1 (14.3) |
2 (25) |
8 (14) |
| Congestive heart failure |
10 (23.8) |
3 (42.9) |
5 (62.5) |
18 (31.6) |
| Malignancy |
4(9.5) |
1 (14.3) |
1 (12.5) |
5 (8.8) |
|
Comorbid conditions (%) |
|
|
|
|
| Poor nutritiona |
42 (100) |
7 (100) |
8 (100) |
57 (100) |
| Prior antibiotic useb |
37 (88.1) |
6 (85.7) |
7 (87.5) |
50 (87.7) |
| Previous severe illnessc |
35 (83.3) |
6 (85.7) |
6 (75) |
47 (82.5) |
| Prolonged (>30 days) hospitalization |
33 (78.6) |
5 (71.4) |
6 (75) |
44 (77.2) |
| Prior use of 3rd-generation cephalosporin |
27 (64.3) |
5 (71.4) |
6 (75) |
38 (66.7) |
| ICU stay at or after the onset of bacteremia |
20 (47.6) |
4 (57.1) |
5 (62.5) |
29 (50.9) |
|
Pitt bacteremia score |
5.29 ± 1.67 |
5 ± 1.73 |
6.38 ± 2.26 |
5.4 ± 1.78 |
|
ABx after onset of bacteremiad |
|
|
|
|
| Effective ABx within 5 days (%) |
15 (35.7) |
3 (42.9) |
3 (37.5) |
21 (36.8) |
| Use flomoxef/IMP /MEP as effective ABx(%) |
19(45)/13(31)/ 10(24) |
4(57)/3(43)/ none |
6 (75)/none/ 2(25) |
29(51)/16(28)/ 12(21) |
| Mortality (%) | 27 (64.3) | 3 (42.9) | 6 (75) | 36 (63.2) |
a albumin < 3.5 g/dL; b including extended-spectrum cephalosporins, aztreonam, fluoroquinolones, trimethoprim/sulfamethoxazole, or aminoglycosides; c includes shock, intubation and ICU stay; d Abx: antibiotics, IMP: imipenem, MEP: meropenem.